|Other names||FK-435; ICI-79280; K-060; K-21060E; RP-60850; 3-Hydroxytamoxifen; 3-OH-TAM|
|Elimination half-life||19–37 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||387.523 g·mol−1|
|3D model (JSmol)|
Droloxifene (INN, USAN) (former developmental code names FK-435, ICI-79280, K-060, K-21060E, RP-60850), also known as 3-hydroxytamoxifen, is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that was developed originally in Germany and later in Japan for the treatment of breast cancer, osteoporosis in men and postmenopausal women, and cardiovascular disorders but was abandoned and never marketed. It reached phase II and phase III clinical trials for these indications before development was discontinued in 2000. The drug was found to be significantly less effective than tamoxifen in the treatment of breast cancer in two phase III clinical trials.
Droloxifene is an analogue of tamoxifen, specifically 3-hydroxytamoxifen, but has 10- to 60-fold increased affinity for the estrogen receptor and reduced partial estrogen agonistic activity. It causes a dose-dependent decrease in luteinizing hormone and follicle-stimulating hormone levels, indicating that it has antigonadotropic activity, and dose-dependently increases sex hormone-binding globulin levels, indicating that it has estrogenic activity in the liver. Similarly to tamoxifen, droloxifene has partial estrogenic effects in the uterus. Unlike tamoxifen, droloxifene does not produce DNA adduct or liver tumors in animals.